Preliminary safety and efficacy of boven (Zanubrutinib, Obinutuzumab, and Venetoclax) as frontline therapy for older patients with Mantle Cell Lymphoma
Clinical trial demonstrates a 2-year progression-free survival of 86% in older patients with Mantle Cell Lymphoma, suggesting BOVen is a promising frontline therapy.
Key Points
The BOVen triplet achieved a complete response rate of 94% in older patients with Mantle Cell Lymphoma.
Progression-free survival at 2 years was 86%, indicating effectiveness of the treatment strategy.
This phase II clinical trial involved patients with untreated mantle cell lymphoma, specifically including those with TP53 mutations.
Results suggest the BOVen regimen is safe, with a toxicity profile comparable to previous studies on targeted therapies.